Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 18, 2026 | May 20, 2026 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | Director | November 08, 2019 | November 12, 2019 |
| SI-BONE, Inc.SIBN · Entity 2501 | Director | June 04, 2026 | June 08, 2026 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 06, 2024 | June 10, 2024 |
| TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285 | Director | December 10, 2019 | December 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,952 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Sale · Disposed 20 · Balance 83,952 |
| Common StockSEC Table I · non-derivative | IndirectBy: John Freund Family Partnership IV, L.P. | 23,129 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 23,129 F1: The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The Reporting Person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The Reporting Person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy: Skyline Venture Management V, LLC | 8,625 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 8,625 F2: The shares are held by Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management V, LLC. The Reporting Person disclaims beneficial ownership of all the shares held by Skyline Venture Management V, LLC except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The Reporting Person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The Reporting Person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein.
F2: The shares are held by Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management V, LLC. The Reporting Person disclaims beneficial ownership of all the shares held by Skyline Venture Management V, LLC except to the extent of his proportionate pecuniary interest therein.
Protara Therapeutics, Inc.
Report date November 08, 2019 · Filed November 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,175,882 |
Reported balance
After 2019-11-08 transaction · row 1
1 source rowRow 1 · 2019-11-08 · Conversion · Acquired 703,588 · Balance 2,175,882 F1: The shares of Series A Convertible Preferred Stock (the "Series A Stock") are exercisable at any time at the option of the holder into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. The Series A Stock has no expiration date and contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding. F2: On November 8, 2019, Skyline Venture Partners Qualified Purchaser Fund IV, LP. ("Skyline") converted 700 shares of Series A Stock, resulting in the issuance to Skyline of 703,558588 shares of Common Stock. The reporting person is a Managing Director of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.99 | IndirectSee footnote | 354 |
Reported balance
After 2019-11-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-08 · Conversion · Disposed 700 · Balance 354 F1: The shares of Series A Convertible Preferred Stock (the "Series A Stock") are exercisable at any time at the option of the holder into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. The Series A Stock has no expiration date and contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding. F2: On November 8, 2019, Skyline Venture Partners Qualified Purchaser Fund IV, LP. ("Skyline") converted 700 shares of Series A Stock, resulting in the issuance to Skyline of 703,558588 shares of Common Stock. The reporting person is a Managing Director of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series A Convertible Preferred Stock (the "Series A Stock") are exercisable at any time at the option of the holder into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. The Series A Stock has no expiration date and contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.
F2: On November 8, 2019, Skyline Venture Partners Qualified Purchaser Fund IV, LP. ("Skyline") converted 700 shares of Series A Stock, resulting in the issuance to Skyline of 703,558588 shares of Common Stock. The reporting person is a Managing Director of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
SI-BONE, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,258 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,957 · Balance 54,258 F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Common StockSEC Table I · non-derivative | IndirectBy John Freund Family Partnership IV, L.P | 91,767 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 91,767 F3: Shares held by John Freund Family Partnership IV, L.P. ("Family LP"). Reporting Person, a member of Issuer's board of directors, is a general partner of Family LP and may be deemed to have voting and investment power with respect to the securities held by Family LP. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.
F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: Shares held by John Freund Family Partnership IV, L.P. ("Family LP"). Reporting Person, a member of Issuer's board of directors, is a general partner of Family LP and may be deemed to have voting and investment power with respect to the securities held by Family LP. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
SUTRO BIOPHARMA, INC.
Report date June 06, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2034-06-06 | Direct | 35,000 |
Reported balance
After 2024-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 35,000 · Balance 35,000 F1: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.
TETRAPHASE PHARMACEUTICALS INC
Report date December 10, 2019 · Filed December 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Skyline Venture Management IV, LLC | 0 |
Reported balance
After 2019-12-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-12-10 · Sale · Disposed 14,507 · Balance 0 F1: The numbers of shares of common stock reported on this Form 4 reflects a 1-for-20 reverse stock split effected on September 26, 2019. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.10 to $2.25 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3: The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. ("SVP IV"). The reporting person is a member of Skyline Venture Management IV, LLC, which serves as the sole general partner of SVP IV, and may be deemed to share voting and dispositive power over the shares held by SVP IV. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-10 transaction · row 2
1 source rowRow 2 · 2019-12-10 · Sale · Disposed 524 · Balance 0 F1: The numbers of shares of common stock reported on this Form 4 reflects a 1-for-20 reverse stock split effected on September 26, 2019. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.10 to $2.25 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The numbers of shares of common stock reported on this Form 4 reflects a 1-for-20 reverse stock split effected on September 26, 2019.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.10 to $2.25 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. ("SVP IV"). The reporting person is a member of Skyline Venture Management IV, LLC, which serves as the sole general partner of SVP IV, and may be deemed to share voting and dispositive power over the shares held by SVP IV. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 21:41 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 10,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001296771-26-000005 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,258 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 20 | $34.05 | $681.00 |
DisclosureSEC source: 0001296771-26-000004 · form4-05202026_040501.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,952 Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 8,700 | $0.00 Strike: $16.49 | $0.00 |
DisclosureSEC source: 0001296771-26-000002 · form4-05182026_040512.xml · derivative · entry 6 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,700 shares Expires 2026-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,127 | $34.54 | $142,546.58 |
DisclosureSEC source: 0001296771-26-000002 · form4-05182026_040512.xml · nonDerivative · entry 3 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,972 Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 8,700 | $16.49 | $143,463.00 |
DisclosureSEC source: 0001296771-26-000002 · form4-05182026_040512.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 8,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001296771-26-000002 · form4-05182026_040512.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,399 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 22:09 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 12,132 | $15.99 | $193,997.96 |
DisclosureSEC source: 0001562180-25-005706 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John Freund Family Partnership IV, L.P Disclosed balance after: 91,767 F1 · price: This transaction was executed in multiple trades at prices ranging from $15.80 USD to $16.3950 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by John Freund Family Partnership IV, L.P. ("Family LP"). Reporting Person, a member of Issuer's board of directors, is a general partner of Family LP and may be deemed to have voting and investment power with respect to the securities held by Family LP. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 11,659 | $34.36 | $400,640.55 |
DisclosureSEC source: 0001062993-25-014202 · form4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By: John Freund Family Partnership IV, L.P. Disclosed balance after: 23,129 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.27 to $34.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The Reporting Person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The Reporting Person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:04 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 15,000 | $0.00 Strike: $13.45 | $0.00 |
DisclosureSEC source: 0001062993-25-011425 · form4.xml · derivative · entry 5 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:04 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,601 | $30.62 | $202,149.02 |
DisclosureSEC source: 0001062993-25-011425 · form4.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,658 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.62 to $30.628, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:04 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 15,000 | $13.45 | $201,750.00 |
DisclosureSEC source: 0001062993-25-011425 · form4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 23:44 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004608 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,301 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,675 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:42 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009806 · form4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,259 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 21:52 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005334 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,626 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,791 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001415889-24-016209 · form4-06102024_080606.xml · derivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 16, 2024 Filed May 16, 2024 23:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 7,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010540 · form4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,468 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:24 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 30,000 | $20.54 | $616,197.00 |
DisclosureSEC source: 0001562180-23-006298 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John Freund Family Partnership IV, LP Disclosed balance after: 103,899 F1 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.09 to $21.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by John Freund Family Partnership IV, L.P. ("Family LP"). Reporting Person, a member of Issuer's board of directors, is a general partner of Family LP and may be deemed to have voting and investment power with respect to the securities held by Family LP. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:26 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 4,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005109 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,835 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 4,866 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:32 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036467 · doc4.xml · derivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 8, 2023, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2024 annual stockholders meeting or June 8, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:39 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011817 · form4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,775 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:05 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005236 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,969 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,324 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:01 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-22-035205 · doc4.xml · derivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 14,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-013302 · form4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,983 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| June 16, 2021 Filed Jun 16, 2021 21:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 12,591 | $31.41 | $395,426.65 |
DisclosureSEC source: 0001562180-21-004319 · primarydocument.xml · nonDerivative · entry 3 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 331,366 F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $30.84 to $31.96, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F4 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 21,511 | $31.11 | $669,136.22 |
DisclosureSEC source: 0001562180-21-004319 · primarydocument.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 343,957 F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $30.74 to $31.75, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 17,990 | $31.28 | $562,737.99 |
DisclosureSEC source: 0001562180-21-004319 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 365,468 F1 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $31.09 to $31.65, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:41 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 3,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004257 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,645 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 3,848 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:02 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $18.21 | $0.00 |
DisclosureSEC source: 0001209191-21-038680 · doc4.xml · derivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 3, 2021, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2022 annual stockholders meeting or June 3, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 21:33 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 45,220 | $30.06 | $1,359,444.34 |
DisclosureSEC source: 0001562180-21-003880 · primarydocument.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 383,458 F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $29.67 to $30.99, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:33 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 26,367 | $30.93 | $815,523.40 |
DisclosureSEC source: 0001562180-21-003880 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 428,678 F1 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $30.43 to $31.76, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 26, 2021 Filed May 26, 2021 23:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 17,138 | $31.85 | $545,833.30 |
DisclosureSEC source: 0001562180-21-003755 · primarydocument.xml · nonDerivative · entry 4 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 455,045 F5 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $31.55 to $32.00, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 25, 2021 Filed May 26, 2021 23:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,696 | $32.55 | $55,196.66 |
DisclosureSEC source: 0001562180-21-003755 · primarydocument.xml · nonDerivative · entry 3 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 472,183 F4 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $32.50 to $32.70, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 24, 2021 Filed May 26, 2021 23:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 200 | $32.76 | $6,552.00 |
DisclosureSEC source: 0001562180-21-003755 · primarydocument.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 473,879 F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $32.75 to $32.77, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 24, 2021 Filed May 26, 2021 23:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 50,827 | $32.54 | $1,653,956.32 |
DisclosureSEC source: 0001562180-21-003755 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 474,079 F1 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $32.50 to $32.65, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:34 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000460 · edgar.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,948 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2022, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 22:25 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 600,000 | $30.25 | $18,150,000.00 |
DisclosureSEC source: 0001562180-21-002352 · primarydocument.xml · nonDerivative · entry 3 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 524,906 F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 22:25 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 66,200 | $31.63 | $2,093,687.54 |
DisclosureSEC source: 0001562180-21-002352 · primarydocument.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 1,124,906 F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $30.11 to $32.19, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:25 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 55,053 | $30.33 | $1,669,884.11 |
DisclosureSEC source: 0001562180-21-002352 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 1,191,106 F1 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $30.01 to $31.07, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 22:35 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 80,887 | $30.90 | $2,499,586.25 |
DisclosureSEC source: 0001562180-21-002250 · primarydocument.xml · nonDerivative · entry 3 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 1,246,159 F1 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 22:35 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 91,072 | $31.39 | $2,858,859.37 |
DisclosureSEC source: 0001562180-21-002250 · primarydocument.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 1,327,046 F1 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 22:35 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 63,928 | $31.05 | $1,984,740.65 |
DisclosureSEC source: 0001562180-21-002250 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 1,418,118 F1 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 23:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | OtherCommon Stock | 56,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063314 · doc4.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By partnership Disclosed balance after: 56,327 F1 · kind: The shares reported on this form represent pro rata distributions, and not sales or purchases, of securities by the reporting entity to its partners. F3 · ownership.nature: These securities are held of record by the John Freund Family Partnership IV, L.P. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 23:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | OtherCommon Stock | 118,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063314 · doc4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Management V, LLC Disclosed balance after: 0 F1 · kind: The shares reported on this form represent pro rata distributions, and not sales or purchases, of securities by the reporting entity to its partners. F2 · ownership.nature: These securities are held of record by Skyline Venture Management V, LLC ("Skyline Management"), of which the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors, and each may be deemed to share voting and investment power over the securities held by Skyline Management. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 03, 2020 Filed Dec 5, 2020 01:35 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 47,886 | $23.39 | $1,120,197.20 |
DisclosureSEC source: 0001562180-20-007090 · primarydocument.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 1,482,046 F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $22.95 to $23.6950, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F4 · balance_after: Reflects a previous pro rata distribution by Skyline Venture Partners V, L.P. ("SVP V") of 500,000 shares, for no consideration. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2020 Filed Dec 5, 2020 01:35 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 100,000 | $23.28 | $2,328,480.00 |
DisclosureSEC source: 0001562180-20-007090 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, LP Disclosed balance after: 1,529,932 F1 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $22.45 to $23.43, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by SVP V. Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | OtherCommon Stock | 118,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-057999 · doc4.xml · nonDerivative · entry 2 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Management V, LLC Disclosed balance after: 118,735 F1 · kind: The shares reported on this form represent pro rata distributions, and not sales or purchases, of securities by the reporting entity to its partners for which it acts as nominee without consideration. F3 · ownership.nature: These securities are held of record by Skyline Management, of which the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors, and each may be deemed to share voting and investment power over the securities held by Skyline Management. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:59 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | OtherCommon Stock | 560,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-057999 · doc4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 F1 · kind: The shares reported on this form represent pro rata distributions, and not sales or purchases, of securities by the reporting entity to its partners for which it acts as nominee without consideration. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 22:27 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 190,053 | $22.00 | $4,181,166.00 |
DisclosureSEC source: 0001562180-20-006399 · primarydocument.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 2,129,932 F1 · kind: Shares were sold in conjunction with the Issuer's public offering of common stock announced on October 14, 2020. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Reporting Person, a member of Issuer's board of directors, is a managing director of LLC and may be deemed to have voting and investment power with respect to the securities held by SVP V. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 20:56 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 400,000 | $12.00 | $4,800,000.00 |
DisclosureSEC source: 0001209191-20-051490 · doc4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 560,053 F1 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 21:15 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | SaleCommon Stock | 500,000 | $10.00 | $5,000,000.00 |
DisclosureSEC source: 0001209191-20-050511 · doc4.xml · nonDerivative · entry 1 Freund John Gordon · CIK 0001296771 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 960,053 F1 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.